There are currently 89 active clinical trials seeking participants for Lymphoma research studies. The states with the highest number of trials for Lymphoma participants are Ohio, Illinois, California and New York.
Transplant Wellness Clinic for Elderly or High Risk Patients Undergoing BMT
NCT04194840
Recruiting
As the average age of individuals undergoing stem cell transplant continues to increase, challenges associated with balancing the side effects of cancer treatments while also managing other medical conditions develop. Studies have shown these individuals develop more treatment related side effects and take longer to leave the hospital due to complications. The purpose of this study is to develop a multiple provider clinic that will help identify any additional needs in the more complicated and g... Read More
Gender:
All
Ages:
All
Trial Updated:
04/02/2024
Locations: University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Stem Cell Transplant Complications, Myeloma, Lymphoma, Allogeneic and Autologous Stem Cell Transplant
Register for Updates
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
NCT06131801
Recruiting
The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown. Primary Objectives • To determ... Read More
Gender:
All
Ages:
Between 0 years and 38 years
Trial Updated:
01/24/2024
Locations: Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio
Conditions: Hematologic Malignancy, Leukemia, Lymphoma, Acute Lymphocytic Leukemia, ALL, Acute Myelogenous Leukemia, AML, Chronic Myelogenous Leukemia, CML, Myeloproliferative Neoplasm, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, T-cell Lymphoma, B Cell Lymphoma, Peripheral T Cell Lymphoma, Cutaneous B-Cell Lymphoma
Register for Updates
Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma
NCT02106988
Recruiting
The goal of this clinical research study is to learn if radiation therapy and chemotherapy can help control Stage 1 and/or 2 NK cell lymphoma. The safety of the radiation and chemotherapy combination will also be studied. This is an investigational study. Radiation and chemotherapy are FDA approved and commercially available for patients with Stage 1 and/or 2 NK cell lymphoma. The combination of these therapies given at the same time is investigational. Up to 40 patients will take part in this... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Lymphoma
Register for Updates
A Study of Mosunetuzumab in People With Follicular Lymphoma
NCT05389293
Recruiting
The purpose of this study is to find out if mosunetuzumab is an effective treatment in people with follicular lymphoma that was recently diagnosed and have not yet received any treatments for their disease.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/21/2024
Locations: Georgetown University (Data Collection Only), Washington, District of Columbia +8 locations
Conditions: Follicular Lymphoma, Lymphoma
Register for Updates
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
NCT01441089
Recruiting
Background: - Some genes may be associated with a greater chance of side effects during cancer treatment. These genes may also make certain treatments less effective. Researchers want to collect blood or cheek swab samples from people having cancer treatment to study these genes. Objectives: - To obtain a blood or cheek swab sample to study genetic differences that may affect cancer treatment. Eligibility: - Individuals with cancer who are being treated at the National Cancer Institute. De... Read More
Gender:
All
Ages:
3 years and above
Trial Updated:
06/19/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostate Cancer, Breast Cancer, Lung Cancer, Ovarian Cancer, Lymphoma
Register for Updates
A Phase I Study: PET Imaging of Cancer Patients Using [18F] 4-L-Fluoroglutamine (2S,4R)
NCT01697930
Recruiting
This is a Phase I study. This study is the first time that a new experimental drug called 18FFluoroglutamine, or F-Glutamine, is being used in people. F-Glutamine is a drug designed to be used with PET scanners that can 'see' where F-Glutamine goes in the body, after its injected. PET scanners are one of the kinds of scanners you normally find in a hospital radiology department. The researchers have found that tumors in animals absorb F-Glutamine. The researchers believe that scans with F-Glutam... Read More
Gender:
All
Ages:
Between 21 years and 90 years
Trial Updated:
06/19/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Solid Malignancy, Lymphoma
Register for Updates
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
NCT05540340
Recruiting
The purpose of this study is to find out whether it is practical to use a newer way to calculate melphalan dose given (called population PK model) in BEAM chemotherapy before AHCT. Standard dose is fixed for everybody and is calculated using height and weight. The population PK model, tested in this study, uses information based on people who have previously received melphalan and aims to calculate an optimal dose separately for each person. Study researchers think that the dose calculated using... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/19/2024
Locations: Memorial Sloan Kettering Cancer Center, New York, New York
Conditions: Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Hodgkin, Lymphoma, Non-Hodgkin
Register for Updates
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936
Recruiting
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/17/2024
Locations: City of Hope Cancer Center, Duarte, California +51 locations
Conditions: Lymphoma
Register for Updates
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
NCT05135351
Recruiting
Higher gut microbiome diversity has been associated with improved survival following autologous stem cell transplantation in multiple myeloma and lymphoma. This study hypothesises that prebiotic supplementation with resistant starch (RS) will improve gut microbiome diversity at time of stem cell engraftment. To test this, participants will either have RS or a placebo (maltodextrin) mixed into a food item of their choice for approximately 10 days prior to stem cell infusion and continue to the fi... Read More
Gender:
All
Ages:
19 years and above
Trial Updated:
06/14/2024
Locations: Unversity of Nebraska Medical Center, Omaha, Nebraska
Conditions: Multiple Myeloma, Lymphoma
Register for Updates
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
NCT03223610
Recruiting
Background: B-cell lymphoma is a cancer of white blood cells found in the lymph nodes. It affects the system that fights infections and disease. Researchers want to learn how certain drugs work together to treat B-cell lymphomas. The drugs are venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR). Objective: To study the safety of ViPOR for people with B-cell lymphoma. Eligibility: People ages 18 and older with B-cell lymphoma whose cancer has returned or not improved af... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/14/2024
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Lymphoma, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma
Register for Updates
Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
NCT02323867
Recruiting
This is a single arm pilot study for patients using α/β T cell-depleted peripheral Stem Cell Transplantation (PSCT) in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and graft versus host disease (GVHD), and one year leukemia free survival.
Gender:
All
Ages:
23 years and below
Trial Updated:
06/13/2024
Locations: The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
Conditions: Leukemia, Lymphoma, Myelodysplasia
Register for Updates
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763
Recruiting
CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/13/2024
Locations: University of Alabama at Birmingham, Birmingham, Alabama +29 locations
Conditions: Lymphoma, Non-Hodgkin, Relapsed Non Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Non Hodgkin Lymphoma, Lymphoma, B Cell Lymphoma, B Cell Non-Hodgkin's Lymphoma
Register for Updates